We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Microbiome therapeutics company Seres Therapeutics has announced that a Phase IIb study of its potential ulcerative colitis (UC) candidate SER-287 failed to meet its primary endpoint.